BioPharmSignal logoBioPharmSignal

Biotech News

TCBP Announces Transition from Nasdaq to OTC Markets

TC BioPharm (TCBP)TC BioPharmCompany update

TCBP (TCBP) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is tcbp.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

TC BioPharm

TC BioPharm is a cell-therapy biotechnology company focused on gamma delta T-cell approaches for cancer and related immune applications. Its story is built around a narrow platform that tries to create differentiated anti-cancer activity through engineered immune cells.

Recent company news

TCBPTC BioPharm2025-06-11 12:30 EST

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TCBPTC BioPharm2025-04-09 13:00 EST

TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells

TCBPTC BioPharm2025-03-21 14:45 EST

TCBP Announces Transition from Nasdaq to OTC Markets

TCBPTC BioPharm2025-03-18 12:03 EST

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

TCBPTC BioPharm2025-03-05 13:30 EST

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States